SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017414
Filing Date
2022-11-10
Accepted
2022-11-10 16:11:36
Documents
88
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ganx-20220930x10q.htm   iXBRL 10-Q 2071851
2 EX-31.1 ganx-20220930xex31d1.htm EX-31.1 10936
3 EX-31.2 ganx-20220930xex31d2.htm EX-31.2 10404
4 EX-32.2 ganx-20220930xex32d2.htm EX-32.2 10308
  Complete submission text file 0001558370-22-017414.txt   8183135

Data Files

Seq Description Document Type Size
5 EX-101.SCH ganx-20220930.xsd EX-101.SCH 58927
6 EX-101.CAL ganx-20220930_cal.xml EX-101.CAL 61371
7 EX-101.DEF ganx-20220930_def.xml EX-101.DEF 203435
8 EX-101.LAB ganx-20220930_lab.xml EX-101.LAB 519243
9 EX-101.PRE ganx-20220930_pre.xml EX-101.PRE 391001
82 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20220930x10q_htm.xml XML 1320520
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

IRS No.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40237 | Film No.: 221377266
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences